The Blackstone Group agreed to buy Ayumi Pharmaceutical, a Japanese maker of anti-rheumatism drugs, from Unison Capital for a reported $1 billion.
Why it's the BFD: Because it's Blackstone's first-ever buyout in Japan, and comes as many other U.S. and European private equity firms are seeking deals in a country they had spent over a decade ignoring. "We are seeing much more deal flow in Japan," said Kewsong Lee, co-CEO of The Carlyle Group, speaking last month at the SuperReturn event in Berlin. "It is the third largest economy in the world, but private-equity penetration there is much lower."
